Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 121–130, page 13 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorieResearch summary

   Research summaries · alzhub.org/study/lecanemab-e-la-malattia-di-alzheimer-perusini-tra-speranze-40637522

   … developed and one of them (lecanemab) recently received marketing authorization by the European Medicines Agency (Ema). Although they represent an important innovation in the treatment of AD, their clinical net benefit is …

2. Lecanemab in clinical practice: real-world outcomes in early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-in-clinical-practice-real-world-outcomes-in-early-alzheimer-40437535

   … screened and 86 initiated lecanemab treatment. In the intention-to-treat (ITT) population, MMSE scores declined significantly over 6 months (F(1, 45.13) = 7.41, p =.009). Subgroup analysis revealed a significant decline in …

3. Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA)Research summary

   Research summaries · alzhub.org/study/lecanemab-in-practice-ai-derived-mri-predictors-of-benefit-and-42374501

   Introduction Lecanemab, a monoclonal antibody targeting amyloid beta, has demonstrated meaningful clinical benefits in early Alzheimer's disease (AD), yet real-world data is needed to optimize patient selection and enhance safety …

4. Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in ChinaResearch summary

   Research summaries · alzhub.org/study/lecanemab-treatment-for-alzheimer-s-disease-of-varying-severities-and-41070709

   … biomarker dynamics of Lecanemab in Chinese patients with Alzheimer's disease (AD). Methods A multi-center prospective cohort study enrolled 68 AD patients. Cognitive scales and plasma biomarkers were assessed at baseline (V0), …

5. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world studyResearch summary

   Research summaries · alzhub.org/study/lecanemab-use-in-chinese-patients-with-alzheimer-s-disease-a-12-month-42557932

   Introduction We evaluated lecanemab's safety and cognitive outcomes in Chinese patients with Alzheimer's disease (AD) and the utility of blood-based biomarkers (BBMs) for treatment guidance. Methods A multicenter, real-world …

6. Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/population-pharmacokinetics-and-exposure-response-analyses-of-safety-39207112

   Lecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild dementia due to …

7. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacologyResearch summary

   Research summaries · alzhub.org/study/post-marketing-safety-of-lecanemab-a-real-world-study-based-on-faers-42440762

   Introduction Lecanemab is a monoclonal antibody targeting amyloid-beta (Aβ) approved for treating Alzheimer's disease (AD) with mild cognitive impairment or mild dementia. Continuous monitoring of its real-world safety profile …

8. Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance studyResearch summary

   Research summaries · alzhub.org/study/post-marketing-safety-signals-and-report-level-aria-e-stratification-42621237

   … adverse event profiles of lecanemab (LEC) and donanemab (DON), identify report-level factors associated with ARIA-E, and develop a machine learning model for ARIA-E risk stratification. Multivariable logistic regression was used …

9. Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/safety-of-switching-from-lecanemab-to-donanemab-in-20-consecutive-40708311

   … disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were observed during the first five donanemab infusions. Prior exposure to lecanemab may reduce …

10. [Anti-amyloid antibodies against Alzheimer's disease : Lecanemab and donanemab in practice-Clinical importance, patient selection and safety management]Research summary

    Research summaries · alzhub.org/study/anti-amyloid-antibodies-against-alzheimer-s-disease-lecanemab-and-42853396

    Lecanemab and donanemab are the first disease-modifying therapies for early Alzheimer's disease. These humanized IgG1 antibodies promote the clearance of aggregated amyloid-beta peptides and, in the pivotal CLARITY AD and …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.